Co‐inhibitory profile and cytotoxicity of CD57⁺PD‐1^– T cells in end‐stage renal disease patients

E-ISSN： 1365-2249|191|3|363-372

ISSN： 0009-9104

Source： CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.191, Iss.3, 2018-03, pp. : 363-372

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferasirox in thalassemia patients with end‐stage renal disease

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 91, Iss. 10, 2016-10 ,pp. : E456-E457

John Wiley & Sons Inc

Access to resources Recommend Favorite

High‐density lipoprotein from end‐stage renal disease patients exhibits superior cardioprotection and increase in sphingosine‐1‐phosphate

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (ELECTRONIC), Vol. 48, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevalence of Prostate Cancer in End-Stage Renal Disease Patients

Urologia Internationalis, Vol. 80, Iss. 4, 2008-06 ,pp. : 419-424

Karger

Access to resources Recommend Favorite

Hypertension – A Possible Vulnerability Marker for Depression in Patients with End-Stage Renal Disease

Nephron Clin Pract, Vol. 102, Iss. 1, 2005-09 ,pp. : c43-c50

Karger

Access to resources Recommend Favorite

Antibody Response to Hepatitis B Vaccine in End-Stage Renal Disease Patients

Nephron Clin Pract, Vol. 103, Iss. 3, 2006-03 ,pp. : c89-c93

Karger

Access to resources Recommend Favorite